Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Research & Development (2023 - 2026)

Contineum Therapeutics' Research & Development history spans 4 years, with the latest figure at $11.6 million for Q1 2026.

  • Quarterly Research & Development fell 15.05% to $11.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $49.5 million through Mar 2026, up 11.5% year-over-year, with the annual reading at $51.5 million for FY2025, 34.1% up from the prior year.
  • Research & Development came in at $11.6 million for Q1 2026, down from $12.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $14.1 million in Q2 2025 to a low of $3.6 million in Q1 2023.
  • The 4-year median for Research & Development is $9.7 million (2024), against an average of $9.9 million.
  • The largest YoY upside for Research & Development was 114.15% in 2024 against a maximum downside of 16.48% in 2024.
  • Contineum Therapeutics' Research & Development stood at $8.0 million in 2023, then surged by 62.44% to $13.0 million in 2024, then decreased by 2.0% to $12.8 million in 2025, then fell by 8.68% to $11.6 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Research & Development are $11.6 million (Q1 2026), $12.8 million (Q4 2025), and $11.0 million (Q3 2025).